Skip to main content

    HC Wainwright & Co. starts coverage of Neurosense Therapeutics (NRSN) at Buy

    GNG Research Market News

    By GNG Research

    HC Wainwright & Co. began covering Neurosense Therapeutics Ltd (NRSN) with a Buy rating on September 3, 2026.

    The past 90 days include one active firm, with zero rating the stock bullish. Six analysts set consensus price targets as of October 30, 2026, with a mean of $98.30, a median of $103.02 and a range of $3.54 to $189.00.

    Consensus Q4 FY2026 EPS is -$3.67, with revenue at $0. The next earnings report is on March 29, 2027.